Other
CMML
0
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
CMML is an early-stage landscape with 0 programs across 5 companies. The most active players are Biocity Biopharmaceutics Co., Ltd., Pfizer, Astex Pharmaceuticals, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Recruiting3 · 30%
Unknown status3 · 30%
Active, not recruiting2 · 20%
Completed2 · 20%
Clinical Trials
Trial Activity
10 trials
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Recruiting·—·Phase 1·NCT05233618·44 enrolled
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Recruiting·—·Phase 2·NCT06630221·25 enrolled
Pacritinib in CMML
Recruiting·—·Phase 1/2·NCT06159491·26 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)